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Persistent type 2 endoleak after endovascular
repair of abdominal aortic aneurysm is associated
with adverse late outcomes
John E. Jones, MD, Marvin D. Atkins, MD, David C. Brewster, MD, Thomas K. Chung, MA,
Christopher J. Kwolek, MD, Glenn M. LaMuraglia, MD, Thomas M. Hodgman, BA, and
Richard P. Cambria, MD, Boston, Mass
Objective: Type 2 endoleak occurs in up to 20% of patients after endovascular aneurysm repair (EVAR), but its long-term
significance is debated. We reviewed our experience to evaluate late outcomes associated with type 2 endoleak.
Methods: During the interval January 1994 to December 2005, 873 patients underwent EVAR. Computed tomography
(CT) scan assessment was performed<1 month of the operation and at least annually thereafter. Sequential 6-month CT
scan follow-up was adopted for those patients with persistent type 2 endoleaks, and reintervention was limited to those
with sac enlargement >5 mm. Study end points included overall survival, aneurysm sac growth, reintervention rate,
conversion to open repair, and abdominal aortic aneurysm (AAA) rupture. Preoperative variables and anatomic factors
potentially associated with these endpoints were assessed using multivariate analysis.
Results:We identified 164 (18.9%) patients with early (at the first follow-up CT scan) type 2 endoleaks. Mean follow-up
was 32.6 months. In 131 (79.9%) early type 2 endoleaks, complete and permanent leak resolution occurred <6 months.
Endoleaks persisted in 33 patients (3.8% of total patients; 20.1% of early type 2 endoleaks) for>6months. Transient type
2 endoleak (those that resolved <6 months of EVAR) was not associated with adverse late outcomes. In contrast,
persistent endoleak was associated with several adverse outcomes. AAA-related death was not significantly different
between patients with and without a type 2 endoleak (P  .78). When evaluating patients with no early endoleak vs
persistent endoleak, freedom from sac expansion at 1, 3, and 5 years was 99.2%, 97.6%, and 94.9% (no leak) vs 88.1%,
48.0%, and 28.0% (persistent) (P < .001). Patients with persistent endoleak were at increased risk for aneurysm sac
growth vs patients without endoleak (odds ratio [OR], 25.9; 95% confidence interval [CI] 11.8 to 57.4; P < .001).
Patients with a persistent endoleak also had a significantly increased rate of reintervention (OR, 19.0; 95% CI, 8.0 to
44.7); P < .001). Finally, aneurysm rupture occurred in 4 patients with type 2 endoleaks. Freedom from rupture at 1, 3,
and 5 years for patients with a persistent type 2 endoleak was 96.8%, 96.8%, and 91.1% vs 99.8%, 98.5%, and 97.4% for
patients without a type 2 endoleak. Multivariate analysis demonstrated persistent type 2 endoleak to be a significant
predictor of aneurysm rupture (P  .03).
Conclusions: Persistent type 2 endoleak is associated with an increased incidence of adverse outcomes, including aneurysm
sac growth, the need for conversion to open repair, reintervention rate, and rupture. These data suggest that patients with
persistent type 2 endoleak (>6 months) should be considered for more frequent follow-up or a more aggressive approach
to reintervention. (J Vasc Surg 2007;46:1-8.)Endovascular abdominal aortic aneurysm repair
(EVAR) is an increasingly used method of repairing ab-
dominal aortic aneurysms (AAAs) in patients with suitable
anatomy.1 This less invasive technique has been established
as a safe and effective method of short-term aneurysm
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doi:10.1016/j.jvs.2007.02.073exclusion.2-5 However, unique mid-term and long-term
graft-specific complications related to EVAR continue to
present management dilemmas for clinicians.6,7 Principal
among these adverse events is the presence of type 2
endoleaks, which occur at some interval after EVAR in 20%
to 30% of patients.8
The more frequent need for reintervention, the re-
quirement for close, long-term surveillance in patients with
type 2 endoleaks and the potential for late conversion to
open repair have tempered the enthusiasm for EVAR and
focused uncertainty about the long-term durability of the
procedure.9,10 The lack of data on late outcomes associated
with type 2 endoleaks has contributed to the wide variety of
approaches to their management currently found in the
literature.11,12 Some authors advocate intervention on all
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rysm sac size.13 The rationale for early reintervention in-
cludes risk of rupture with continued endoleak, lack of
patient compliance with the close follow-up needed with
persistent endoleaks, and the cost and potential negative
renal effects of long-term computed tomography (CT) scan
surveillance.
Other investigators advocate a more conservative ap-
proach to type 2 endoleaks.14-17 These authors cite the
extremely low incidence of aneurysm rupture associated
with type 2 endoleaks. Furthermore, some have demon-
strated that the cost of early reintervention is actually
greater than sequential radiographic follow-up because
many type 2 endoleaks resolve spontaneously within
months of EVAR.15
This study examines the incidence and outcomes of
type 2 endoleaks at a single institution during a 12-year
experience with 873 patients undergoing EVAR.
METHODS
During the interval January 1994 to December 2005,
873 patients underwent EVAR at our institution. Patients
with thoracic aortic aneurysms, anastomotic aortic aneu-
rysms, or isolated iliac aneurysms were excluded from anal-
ysis. Clinical and demographic data were collected from
hospital records and surgeons’ office charts. Radiographic
follow-up information was obtained from radiology reports
and through the office notes of the primary surgeon. All CT
scans reported as demonstrating a type 2 endoleak were
reviewed by a vascular surgeon. Any discrepancy in imaging
interpretation was adjudicated by an independent surgeon
blinded to the study.
An enhanced CT scan with 3-mm cuts and three-
dimensional reformatting was used preoperatively to deter-
mine if each patient presenting for EVAR met the radio-
logic criteria for stent graft repair. Ten different stent graft
designs were included in this study: custom-made at Mas-
sachusetts General Hospital, Vanguard (Boston Scientific,
Natick, Mass), Cordis (Cordis, Miami Lakes, Fla), LifePath
(Edwards Lifesciences, Irvine, Calif), Ancure/EVT
(Guidant, Indianapolis, Ind), Zenith (Cook, Bloomington,
Ind), Excluder (W.L. Gore & Associates, Flagstaff, Ariz),
AneuRx (Medtronic, Minneapolis, Minn), and Powerlink
(Endologix, Irvine, Calif). Overall results from our EVAR
experience have been published previously.2
Follow-up. All patients received an enhanced CT scan
1 month of the procedure at Massachusetts General
Hospital. All CT scans were performed with intravenous
contrast material and thin collimation. After a nonen-
hanced scan was performed, a bolus injection of contrast
was administered at 4 mL/s, with a 25-second preparation
delay. The images were reconstructed with 2.5-mm cuts.
Delayed-phase images were also obtained for all patients
who underwent EVAR. The average time to the first fol-
low-up CT scan was 12 days. Patients were then clinically
evaluated and underwent CT scans at 6 and 12 months
after EVAR, and then at least yearly thereafter.Only early type 2 endoleaks, defined as those present
1 month of EVAR placement, were evaluated in this
study. The presence of a type 2 leak was determined by CT
scan in nearly all patients. If the radiologist or surgeon
could not differentiate between a type 1, 2, or 3 leak by CT
examination, arteriography was performed. Arteriogram
was rarely needed to determine type of endoleak, however,
and was used in only 11 patients. Eight of these patients
demonstrated a type 3 endoleak, and three had type 1
endoleaks from a distal fixation site. None of the indeter-
minate endoleaks were found to be from a type 2 endoleak.
Patients with early type 2 endoleaks underwent en-
hanced CT scan every 6 months until leak resolution and
then yearly thereafter. Endoleaks were further subdivided
into persistent or nonpersistent leaks. Persistent endoleak
was defined as a type 2 endoleak that did not resolve 6
months, whereas a transient endoleak did resolve 6
months after EVAR.
Outcomes. The primary outcomes examined were
AAA-related death, freedom from rupture, and freedom
from aneurysm sac growth. Freedom from conversion to
open repair and reintervention associated with transient
leaks, persistent type 2 endoleaks, and no early endoleak
were also evaluated. Deaths were identified through hospi-
tal and office charts as well as the Social Security Death
Index database. All deaths associated with persistent type 2
endoleaks were confirmed by intraoperative findings or CT
scans consistent with rupture.
Aneurysm sac growth was defined as growth 5 mm
from the preoperative maximal sac diameter. Preoperative
variables previously identified as potentially associated with
type 2 endoleaks or our end points, or both, were included
in our analysis.18 Anatomic variables including preoperative
aneurysm size, neck width, neck length, presence of con-
comitant iliac aneurysm, size of iliac vessels, and preopera-
tively patent lumbar and inferior mesenteric artery vessels
were also examined in our data collection and analysis.
The decision of whether to reintervene and the method
of treatment were made by the attending surgeon. In
general, type 2 endoleaks were not treated unless they were
associated with aneurysm sac growth 5 mm. Success at
reintervention was defined as resolution of the leak based
on CT scan and a maximal sac diameter that did not
continue to increase. The Institutional Review Board of the
Massachusetts General Hospital approved the study.
Statistical analysis. All statistical analysis was per-
formed using SPSS software (SPSS, Inc, Chicago, Ill).
Preoperative and anatomic variables were assessed for pa-
tients with transient, persistent, and no endoleak by using
analysis of variance with Tukey post hoc analysis. Freedom
from rupture, aneurysm sac growth, conversion to open
repair, and reintervention were assessed by using Kaplan-
Meier life-table analysis, and the log-rank test was used
when subgroups were compared. The Cox regression haz-
ards model was performed to identify variables that influ-
enced late outcomes.
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Overall results. An early type 2 endoleak was found in
164 (18.8%) of 873 patients. Of these, 22 (79.9%) early
endoleaks spontaneously resolved 6 months without re-
intervention, and 33 patients (20.1% of type 2 leaks; 3.8%
of all EVARs) had persistent (6 months) endoleaks. Only
two (6.1%) of the 33 persistent endoleaks resolved sponta-
neously. The median follow-up for all patients was 28.7
months. For three patients with transient and persistent
endoleak, the mean follow-up was 29.6 months and 44.1
months, respectively.
Preoperative patient characteristics and anatomic vari-
ables for patients with transient, persistent, and no early
endoleaks are summarized in Table I. In addition, no
statistically significant difference in number of preopera-
tively patent lumbar or inferiormesenteric artery vessels was
found in patients with transient and persistent type 2 en-
doleaks (P  .13; relative risk [RR], 0.34; 95% confidence
interval [CI] 0.22 to 0.52). Furthermore, no other signif-
icant differences in anatomic or preoperative variables were
found between patients with transient, persistent, and no
early endoleak.
Abdominal aortic aneurysm sac enlargement. AAA
sac enlargement was noted in 5.9% of patients without an
identifiable type 2 endoleak at the time of their first post-
operative CT scan compared with 17.1% of patients with an
early endoleak (P  .001). Eight patients with a transient
endoleak experienced sac enlargement, and all of these
occurred 1 year after EVAR. In contrast, 54.5% of pa-
tients (18/33) with a persistent endoleak demonstrated sac
enlargement during the follow-up period.
As shown in Fig 1, the freedom from sac enlargement at
1, 3, and 5 years is 99.2%, 97.6%, and 94.9% for those
without a type 2 endoleak vs 88.1%, 48.0%, and 28.0% for
patients with a persistent endoleak (P .001). The median
time to aneurysm sac expansion5 mm for patients with a
Table I. Patient demographics and preoperative variables
Variable
Type 2 endolea
Transient
Patients 131
Mean follow-up (months) 32.6
Age, years (mean) 76.2
Gender-male (%) 81.6
AAA size, mm (mean) 55.6
Neck length, mm (mean) 27.1
Neck width, mm (mean) 24.6
RenalInsufficiency (%) 4.9
PVD (%) 5.8
Smoking history (%) 47.1
COPD (%) 23.5
Coumadin* (%) 12.6
Plavix† (%) 4.9
AAA, Abdominal aortic aneurysm; PVD, peripheral vascular disease; COPD
*Bristol-Myers Squibb, Princeton, NJ.
†Sanofi-Aventis, Bridgewater, NJ.persistent leak was 17.7 months (range, 4.7 to 76 months).As summarized in Table II, patients with persistent en-
doleak had a significantly higher rate of sac enlargement
compared with those without early type 2 leaks (odds ratio
[OR], 2.5; 95% CI, 1.7 to 3.8; P  .01).
Reinterventions. Patients with persistent type 2 en-
doleaks had a significantly higher reintervention rate than
Fig 1. Kaplan-Meier analysis of freedom from aneurysm sac
growth.
iated with type 2 endoleaks
No early type 2 endoleak Psistent
3 709
3.1 28.8
5.7 75.5 .54
8.6 81.1 .79
5.6 56.7 .99
4.4 24.2 .96
4.7 24.2 .78
2.9 15.0 .07
2.9 10.2 .15
1.4 55.9 .44
7.1 25.1 .31
0.0 11.3 .28
8.6 3.2 .13
nic obstructive pulmonary disease.assoc
k
Per
3
4
7
8
5
2
2
5
1
2
, chrothose without endoleak, as is summarized in Table II (RR,
JOURNAL OF VASCULAR SURGERY
July 20074 Jones et al5.5; 95% CI, 3.5 to 8.8; P  .001). Fig 2 represents a
Kaplan-Meier analysis of the influence of persistent en-
doleak on the reintervention rate. The freedom from rein-
tervention rate for patients without a type 2 endoleak at 1,
3, and 5 years was 97.5%, 84.5%, and 77.9% vs 93.4%,
51.7%, and 24.4% for patients with a persistent endoleak (P
 .001).
Overall, 20 catheter-based interventions and one open
reintervention were performed on 16 patients. Also per-
formed were 13 transarterial embolizations, 5 translumbar
embolizations, 2 graft revisions/stents, and 1 lumbar artery
ligation. Nine (56.3%) of 16 patients eventually had suc-
cessful treatment of their persistent endoleak.
Conversion to open repair. Patients with a persistent
type 2 endoleak had a significantly higher rate of conversion
to open repair compared with those without an early en-
Table II. Significance of persistent type 2 endoleaks on
late outcomes after multivariate analysis
Outcome RR 95% CI P
Rupture 3.9 1.7-8.8 .04
Aneurysm sac growth 2.5 1.69-3.78 .01
Reintervention rate 5.5 3.5-8.8 .001
Conversion to open repair 5.3 2.0-13.5 .04
AAA-related death 2.6 0.77-8.8 .12
RR, Relative risk; CI, confidence interval; AAA, abdominal aortic aneu-
rysm.
Fig 2. Kaplan-Meier analysis of freedom from reintervention.doleak (RR, 5.3; 95% CI, 2.0 to 13.5; P  .001), asdescribed in Table II. The median time to conversion to
open repair in these patients was 20 months (mean, 24
months; range, 9 to 33months). Figure 3 depicts a Kaplan-
Meier analysis of freedom from conversion to open repair
for patients with transient, persistent, and no type 2 en-
doleaks. The respective rate for freedom from conversion to
open repair at 1, 3, and 5 years was 98.8%, 97.3%, and
93.7% for no endoleak patients vs 96.7%, 93.1%, and 78.6%
for patients with persistent leak (P  .01).
Three of 33 patients with a persistent type 2 endoleak
required a conversion to open repair. Two patients had
failed prior transarterial embolizations in that the leak was
evident after the procedure. However, the aneurysm sac
size did not increase further after the interventions, so they
were followed expectantly. The AAA in one of these pa-
tients subsequently ruptured. The other patient presented
with rapid expansion (5 mm during 6 months) and
required conversion to open repair. The third patient was
being monitored for a persistent endoleak without sac
expansion. However, the patient presented with a signifi-
cant increase in aneurysm sac size approximately 41months
after EVAR and an open repair was performed.
Aneurysm rupture. Aneurysm rupture occurred in
four patients with an early type 2 endoleak. As summarized
in Table II, patients with a persistent type 2 endoleak had a
higher rate of rupture vs those without early endoleak (RR,
3.9; 95% CI, 1.7 to 8.8; P  .03). Fig 4 illustrates the
Kaplan-Meier analysis for freedom from aneurysm rupture
for patients with transient, persistent, and no early type 2
Fig 3. Kaplan-Meier analysis of freedom from conversion to open
repair.endoleaks. The freedom from rupture rates at 1, 3, and 5
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99.8%, 98.5%, and 97.4% vs 98.7%, 96.2%, and 96.2% for
patients with transient endoleaks, and 96.8%, 96.8%, and
91.1% for patients with persistent type 2 endoleaks. The
median time to rupture for patients with early type 2
endoleaks was 31.6 months (range, 2 days to 37 months).
Two patients with early type 2 endoleaks experienced
aneurysm rupture 6 months of EVAR placement. The
first patient experienced back pain 2 days after EVAR with
a AneuRx endograft, and a CT scan demonstrated a con-
tained rupture. In the operating room, four lumbar arteries
and a middle sacral artery were bleeding briskly. The en-
dograft was replaced with a tube graft, but the patient
eventually died of postoperative complications. The next
patient had an 8-cm aneurysm that was repaired using a
Zenith stent graft. A type 2 leak was noted on the postop-
erative CT scan. At 3 months after EVAR, a CT scan
revealed a continuing type 2 endoleak, but the sac had
decreased 2 mm in size. One month later, the patient
presented with aneurysm rupture. In the operating room,
several lumbar arteries were back-bleeding briskly, and
these were oversewn. The aneurysm sac was closed and the
endograft was left intact. The patient did well and was
discharged 7 days later.
Persistent type 2 endoleaks also ruptured in two pa-
tients. One patient was being followed up for an endoleak
that was not associated with sac enlargement. She pre-
sented to our hospital with back pain and a CT scan
demonstrating a contained rupture. In the operating room,
the aneurysm sac was opened, revealing two bleeding lum-
Fig 4. Kaplan-Meier analysis of freedom from rupture.bar arteries. The proximal and distal attachment sites wereintact. The bleeding vessels were oversewn from within the
sac, and the graft was left in place. The patient did well
postoperatively and no further endoleaks have been noted
on follow-up CT scans.
The second patient had an enlarging aneurysm sac
associated with an endoleak after placement of a custom-
made endograft. A transarterial embolization was unsuc-
cessful. The patient had several comorbidities and did not
want another attempt at embolization. Her aneurysm sac
did not increase further, remaining 5 mm larger than her
preoperative aneurysm size. The patient presented with
aneurysm rupture 2.5 years after EVAR placement, with a
type 2 endoleak on CT scan. The family chose not to
intervene, and the patient died.
Aneurysm-related mortality. Although associated
with several adverse outcomes, persistent type 2 endoleaks
were not associated with an increase in aneurysm-related
mortality compared with patients without a type 2 en-
doleak, as summarized in Table II (RR, 2.6; 95% CI, 0.77
to 8.8; P  .12).
DISCUSSION
The clinical impact of type 2 endoleak after EVAR is
not well established and remains controversial.19,20 Our
data suggest that persistent type 2 endoleaks are significant
contributors to late adverse outcomes after EVAR. Events
such as aneurysm rupture, conversion to open repair, aneu-
rysm sac growth, and the need for reintervention were
significantly increased in patients with persistent endoleak
in our large series. The small sample size may have limited
this study’s ability to evaluate the impact of endoleak on
AAA-related mortality. The incidence of type 2 endoleak
varies between 6% and 30% in large series of EVAR pa-
tients.7,11 The European Collaborators on Stent-Graft
Techniques for AAA and Thoracic Aortic Aneurysm and
Dissection Repair (EUROSTAR) database reports a 9%
incidence of early (at first postoperative CT scan) type 2
endoleak.8 Zarins et al21 reported a 20% incidence of
endoleak at 1 year with the AneuRx device, with 72% of
leaks being type 2 endoleaks. Our overall rate of type 2
endoleak was 18.8%, with spontaneous resolution occur-
ring6months in 79.9% of patients. This rate of resolution
is higher than found in other published reports. For exam-
ple, Sheehan et al22 recently evaluated the effect of en-
dograft brand on the incidence of type 2 endoleak in 1909
patients and reported a spontaneous resolution at 6 months
of only 33%. However, their initial postoperative CT scan
was performed at 1 month after EVAR, whereas we often
perform postimplant CT scans at 1 day after EVAR, before
discharge. Thus, we may be identifying a large number of
endoleaks that would have resolved by the 1-month time
point used in the Sheehan study. This variation may falsely
elevate our spontaneous resolution rate 6 months after
EVAR.
Published reports demonstrate that spontaneous reso-
lution of endoleaks persisting 6 months occurs in 5% to
33% of patients.22,23 Only 6.1% of our persistent endoleaks
resolved spontaneously. Similar to our results, Parent et
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endoleaks after 12 months.
Evaluation of the natural history of persistent endoleaks
is difficult because of the varying management strategies
used to address these leaks. From the EUROSTAR data-
base, van Marrewijk et al8 found type 2 endoleak to be
significantly associated with aneurysm sac growth over
time. Kaplan-Meier analysis revealed that 24% of patients
with type 2 endoleak had sac enlargement at 48 months
compared with 13% without endoleak. At 3 years, 52% of
our patients with persistent endoleak had sac enlargement.
However, aneurysm sac growth in the EUROSTAR series
was defined as enlargement 8 mm vs 5 mm in our
report. Our higher incidence of sac growth may be ex-
plained by this criteria difference. Moreover, patients with
type 2 endoleaks in the EUROSTAR report were not
divided into transient or persistent. Combining both
groups could mask the clinical impact of persistent en-
doleaks.
The EUROSTAR series also reported a significantly
higher rate of reintervention required by patients with a
type 2 endoleak (P  .001). Our data support these find-
ings. However, the EUROSTAR series did not find an
association between type 2 endoleak and conversion to
open repair or rupture, which our study demonstrated.
Other groups have demonstrated adverse events related
to type 2 endoleak.20 Timaran et al24 specifically evaluated
their experience with persistent type 2 endoleaks in 32
(9.2%) of 348 patients, and 13 (41%) exhibited aneurysm
sac enlargement, occurring at a mean of 9.7 months after
EVAR (mean follow-up, 31 months). In our series, 54.5%
of persistent endoleaks were associated with sac enlarge-
ment, but the mean time to aneurysm growth was much
greater (21 months post-EVAR).
It is unclear why our mean time to aneurysm growth
was significantly longer than the Timaran group. However,
in their cohort of persistent endoleaks with stable or shrink-
ing sac size, their mean follow-up was only 25 months.
Perhaps they missed the patients with late sac growth that
we observed in our series. One patient in the Timaran series
died of a confirmed aneurysm rupture. The 5-year actuarial
freedom from rupture for patients with a persistent en-
doleak in the Timaran series was 92%, which is similar to
our rate of 91.1%. Timaran et al also demonstrated a high
rate of conversion to open repair in these patients of 75% at
5 years, which mirrors our experience of 78.6% at 5 years
based on Kaplan-Meier analysis.
Although several groups have identified adverse late
outcomes associated with type 2 endoleaks, other reports
challenge this assertion. Arko et al25 published their expe-
rience with 46 consecutive patients undergoing EVAR, 16
of whom were identified as having persistent endoleaks.
Persistent endoleak had no significant effect on proximal
neck morphology or migration. Although they demon-
strated a significant effect on change in sac size compared
with no endoleak, the mean increase in sac size for persis-
tent endoleaks was only 1.8 mm. No association between
persistent endoleak and either rupture or conversion toopen repair was identified. Thus, these authors concluded
from their short follow-up of 19.7 months that persistent
type 2 endoleak did not pose a significant risk to patients.
In a review of the current literature, there are only five
reports of rupture secondary to type 2 endoleak.24,26,27
Harris et al28 described nine cases of rupture related to type
2 endoleaks from the EUROSTAR database; however,
eight of these ruptures were attributed to concomitant type
1 endoleaks. We report four cases of aneurysm rupture
associated with type 2 endoleak. Two patients had persis-
tent leaks, and two were not associated with aneurysm sac
growth before rupture. The most plausible explanation for
the latter two patients is that they experienced a sudden,
rapid sac expansion leading to rupture that occurred in the
interval between CT scans.
The relationship between patent collateral flow and the
risk of aneurysm growth and rupture has been described. In
a series from the Albany Medical Center group,29 1218
AAAs were repaired using an exclusion and bypass open
technique. Of these, 64% of patients with persistent sac flow
demonstrated sac enlargement, and 26% ruptured.29 The
applicability of this study to EVAR and endoleaks has been
questioned, but our data related to sac enlargement (and
ongoing potential rupture risk) are similar.
Several treatment options are available for the manage-
ment of type 2 endoleaks. Transarterial chemical or coil
embolization techniques, as well as translumbar sac embo-
lization, have been described.30 Laparoscopic or open liga-
tion of feeding vessels have also been advocated as potential
options.31 The success of these techniques varies widely in
the literature, however.
Baum et al32 compared transarterial coil embolization
with translumbar embolization. In the transarterial group,
16 of 20 patients failed treatment (80% failure rate), but 12
(92%) of 13 patients were successfully treated with trans-
lumbar embolization.32 Timaran et al24 had similar results
in catheter-based treatment of persistent endoleaks. A
transfemoral approach achieved only a 38% success rate,
although a 71% success rate was noted with a translumbar
approach.24 In our series, we used both a transarterial and
translumbar approach to the treatment of type 2 endoleaks
and achieved success in 60% of patients. The number of
techniques and varying success rates of reintervention re-
flects the difficulty of treating type 2 endoleaks after EVAR.
As more experience is gained, a consensus on the best
treatment option may emerge.
Our data and others’ suggest that the natural history of
untreated persistent type 2 endoleaks is not necessarily
benign. Our mean follow-up of 43 months in patients with
persistent endoleaks allowed us to demonstrate that the risk
of aneurysm growth and its associated adverse events con-
tinue over an extended follow-up period. In addition, to
our knowledge, our report is the first to demonstrate a
significant relationship between persistent type 2 endoleaks
and aneurysm rupture.
We did not identify any preoperative factors or ana-
tomic variables predictive of persistent endoleak; however,
we did identify a trend towards increased persistent type 2
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Myers Squibb, Princeton, NJ) or Plavix (Sanofi-Aventis,
Bridgewater, NJ). Our small sample size prevents us from
determining whether anticoagulants significantly contrib-
ute to persistent endoleaks.
Previous work from our institution has demonstrated
that the preoperative number of patent lumbar vessels
significantly correlates with the presence of early type 2
endoleaks.33 Zero to three patent lumbar arteries was asso-
ciated with a 13% type 2 endoleak rate, whereas 50% of
patients with six or more patent lumbar arteries had a type
2 endoleak. Similarly, inferior mesenteric artery patency
was associated with an increase in early endoleak. In this
study, we did not find a significant difference in number of
preoperatively patent lumbar vessels between patients with
transient and persistent endoleaks.
Our study is limited by its retrospective nature and the
relatively small number of adverse events. The relatively low
number of patients with persistent endoleaks made Kaplan-
Meier analysis less robust when evaluating late outcomes
3 years. Furthermore, although multivariate analysis
demonstrated persistent endoleak as a significant predictor
of rupture in our series, the Kaplan-Meier P value did not
reach a level of significance. This is likely due to the large
variation in time to rupture in the persistent (591 days) vs
no-leak groups (1175 days), which can skew Kaplan-Meier
log-rank test.
CONCLUSION
Our data demonstrate the negative impact of type 2
endoleaks on patients undergoing EVAR. Patients with a
persistent endoleak are at a significantly increased risk of
aneurysm rupture, sac growth, conversion to open repair,
and reintervention compared with patients without en-
doleak. To prevent these adverse outcomes, a more aggres-
sive approach to management of persistent type 2 endoleak
may be warranted.
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